# ASBP (Aspire Biopharma Holdings, Inc.) - SEC EDGAR Financial Statements

> Aspire Biopharma Holdings, Inc. reported $6.2K in revenue and a net loss of $11.05M for the fiscal year ended December 31, 2025, with a -1.9% gross margin and a -118015.3% operating margin.

- Canonical: https://convexityos.com/fundamentals/ASBP
- Markdown: https://convexityos.com/fundamentals/ASBP.md
- SEC CIK: 0001847345
- Reporting currency: USD
- Latest filing period: June 30, 2026
- Last synced: Nov 21, 2026, 05:13 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001847345&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | $6.2K | Dec 31, 2025 |
| Operating Income | FY 2025 | -$7.32M | -118015.3% margin |
| Net Income | FY 2025 | -$11.05M | -178156.4% net margin |
| Diluted EPS | FY 2025 | -$10.65 | Split-adjusted |
| Free Cash Flow | FY 2025 | -- | Operating CF less CapEx |
| Cash & ST Investments | Jun 30, 2026 | $12.17M | Total debt: -- |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| **Revenue** | $6.2K | -- | -- | -- |
| Cost of Revenue | $6.3K | -- | -- | -- |
| **Gross Profit** | -$116 | -- | -- | -- |
| Research & Development | $924K | $144K | -- | -- |
| Selling, General & Admin | $18.43M | $1.07M | -- | -- |
| Total Operating Expenses | $19.35M | $1.21M | $1.34M | $976K |
| **Operating Income** | -$19.35M | -$1.21M | -- | -- |
| Interest Income | -- | $549K | $5.81M | $4.32M |
| Interest Expense | $8.53M | $98K | $9.0K | -- |
| Income Before Tax | -$24.48M | -$1.31M | -- | -- |
| Income Tax Expense | -- | $1.0K | -- | -- |
| **Net Income** | -$24.48M | -$1.31M | $4.46M | $3.34M |
| **Diluted EPS** | -$16.38 | -$1.90 | -- | -- |
| Basic Shares Outstanding | 1.5M | 689.9K | -- | -- |
| Diluted Shares Outstanding | 1.5M | 689.9K | -- | -- |

### Income Statement (Quarterly)

| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $63K | $28K | -- | $1.9K | -- | -- | -- | -- |
| Cost of Revenue | $51K | $23K | -- | $1.1K | -- | -- | -- | -- |
| **Gross Profit** | -$30K | $5.8K | -- | $884 | -- | -- | -- | -- |
| Research & Development | $233K | $297K | $100K | $208K | $353K | $263K | $116K | $7.0K |
| Selling, General & Admin | $2.19M | $1.36M | $1.75M | $938K | $447K | $15.29M | $551K | $208K |
| Total Operating Expenses | $2.65M | $1.65M | $1.85M | $1.15M | $800K | $15.56M | $668K | $215K |
| **Operating Income** | -$2.68M | -$1.65M | -$1.85M | -$1.15M | -$800K | -$15.56M | -- | -$215K |
| Interest Income | $57K | $5.0K | -- | -- | -- | -- | $67K | $77K |
| Interest Expense | $0 | $1.60M | $6.23M | $1.48M | $528K | $290K | -- | -- |
| Income Before Tax | -$1.27M | -$3.22M | -- | -- | -$1.98M | -$15.94M | -- | -- |
| Income Tax Expense | -- | -- | -- | -- | -- | -- | -- | $1.0K |
| **Net Income** | -$1.27M | -$3.22M | -$4.71M | -$1.85M | -$1.98M | -$15.94M | -$766K | -$216K |
| Basic EPS | -$1.22 | -$20.57 | -- | -$0.04 | -$48.19 | -$504.88 | -- | -$0.01 |
| **Diluted EPS** | -$1.22 | -$20.57 | -- | -$0.04 | -$48.19 | -$504.88 | -- | -$0.01 |
| Basic Shares Outstanding | 1.0M | 156.7K | -- | 49.5M | 41.1K | 31.6K | -- | 27.6M |
| Diluted Shares Outstanding | 1.0M | 156.7K | -- | 49.5M | 41.1K | 31.6K | -- | 27.6M |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $1.00M | $3.6K | -- | $497K | -- |
| **Cash & Short-Term Investments** | $1.00M | $3.6K | -- | $497K | -- |
| Inventory | $253K | -- | -- | -- | -- |
| **Total Current Assets** | $1.31M | $148K | $81K | $1.10M | $293K |
| **Total Non-Current Assets** | $0 | $0 | $19.90M | $299.1M | $0 |
| **Total Assets** | $1.31M | $148K | $19.98M | $300.2M | $293K |
| Accounts Payable | $1.01M | $310K | -- | -- | -- |
| Other Current Liabilities | $354K | $111K | $239K | $123K | -- |
| **Total Current Liabilities** | $7.59M | $1.69M | $403K | $303K | $294K |
| **Total Non-Current Liabilities** | $96K | $0 | $0 | $10.81M | $0 |
| **Total Liabilities** | $7.69M | $1.69M | $403K | $11.12M | $294K |
| Common Stock | $12 | $69 | -- | -- | -- |
| Retained Earnings | -$27.26M | -$2.78M | -$11.29M | -$9.94M | -$25K |
| **Total Stockholders' Equity** | -$6.38M | -$1.54M | -$488K | -$9.94M | -$475 |
| Total Equity | -$6.38M | -$1.54M | -$488K | -$9.94M | -$475 |

### Balance Sheet (Quarterly)

| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $12.17M | $5.86M | $1.00M | $1.95M | $206K | $1.35M | $3.6K | -- |
| **Cash & Short-Term Investments** | $12.17M | $5.86M | $1.00M | $1.95M | $206K | $1.35M | $3.6K | -- |
| Inventory | $288K | $370K | $253K | $35K | -- | -- | -- | -- |
| **Total Current Assets** | $13.47M | $7.12M | $1.31M | $2.40M | $989K | $1.97M | $148K | $62K |
| **Total Non-Current Assets** | $75K | $0 | $0 | $0 | $0 | $0 | $0 | $6.60M |
| **Total Assets** | $13.54M | $7.12M | $1.31M | $2.40M | $989K | $1.97M | $148K | $6.66M |
| Accounts Payable | $972K | $858K | $1.01M | $1.06M | $1.35M | $1.43M | $310K | -- |
| Other Current Liabilities | -- | -- | $354K | -- | -- | $354K | $111K | $329K |
| **Total Current Liabilities** | $1.69M | $3.15M | $7.59M | $13.86M | $10.56M | $8.87M | $1.69M | $6.57M |
| **Total Non-Current Liabilities** | $97K | $96K | $96K | $9.9K | $49K | $49K | $0 | $0 |
| **Total Liabilities** | $1.78M | $3.25M | $7.69M | $13.87M | $10.61M | $8.92M | $1.69M | $6.57M |
| Common Stock | $129 | $17 | $12 | $5.0K | $5.0K | $4.9K | $69 | -- |
| Retained Earnings | -$31.75M | -$30.48M | -$27.26M | -$22.55M | -$20.70M | -$18.72M | -$2.78M | -$15.38M |
| **Total Stockholders' Equity** | $11.76M | $3.87M | -$6.38M | -$11.47M | -$9.62M | -$7.95M | -$1.54M | -$774K |
| Total Equity | $11.76M | $3.87M | -$6.38M | -$11.47M | -$9.62M | -$7.95M | -$1.54M | -$774K |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| Net Income | -$24.48M | -$1.31M | $4.46M | $3.34M |
| Stock-Based Compensation | $14.13M | $0 | -- | -- |
| Change in Inventory | -$253K | -- | -- | -- |
| Change in Payables | -$324K | $248K | -- | -- |
| **Operating Cash Flow** | -$4.92M | -$265K | -$653K | -$1.41M |
| **Investing Cash Flow** | -- | $13.78M | $284.9M | -$294.7M |
| Common Stock Issued | -- | $258K | -- | -- |
| Share Repurchases | -- | -$13.78M | -$284.9M | -- |
| **Financing Cash Flow** | $5.92M | $258K | -$284.8M | $296.6M |
| **Net Change in Cash** | $1.00M | -$7.5K | -$497K | $497K |

### Cash Flow Statement (Quarterly)

| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$1.27M | -$3.22M | -$4.71M | -$1.85M | -$1.98M | -$15.94M | -$766K | -$216K |
| Stock-Based Compensation | $144K | $13K | $0 | $0 | $0 | $14.13M | -- | $0 |
| Change in Inventory | $39K | -$117K | -- | -- | -- | -- | -- | -- |
| Change in Payables | $128K | -$140K | -$47K | -$1.32M | -$80K | $1.12M | $316K | -$57K |
| **Operating Cash Flow** | -$2.12M | -$3.04M | -$928K | -$1.10M | -$1.14M | -$1.75M | $480K | -$496K |
| Common Stock Issued | $9.00M | $8.95M | -- | -- | -- | -- | $0 | $0 |
| **Financing Cash Flow** | $8.43M | $7.89M | -$17K | $2.85M | $0 | $3.09M | -$492K | $492K |
| **Net Change in Cash** | $6.31M | $4.85M | -$944K | $1.74M | -$1.14M | $1.34M | -$13K | -$3.1K |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| **Gross Margin** | -1.9% | -- | -- | -- |
| **Operating Margin** | -312016.9% | -- | -- | -- |
| **Net Profit Margin** | -394725.1% | -- | -- | -- |
| Return on Assets (ROA) | -1865.7% | -885.1% | 22.3% | 1.1% |
| Current Ratio | 0.17x | 0.09x | 0.20x | 3.62x |
| Quick Ratio | 0.14x | 0.00x | -- | 1.64x |
| **Net Income Growth (YoY)** | -- | -129.3% | +33.6% | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -94.0% | -304.1% | -- | -- | -- | -- | -- | -- |
| Return on Assets (ROA) | -81.6% | -165.3% | -1865.7% | -854.7% | -1910.7% | -865.9% | -885.1% | -10.4% |
| Current Ratio | 7.99x | 2.26x | 0.17x | 0.17x | 0.09x | 0.22x | 0.09x | 0.01x |
| Quick Ratio | 7.81x | 2.14x | 0.14x | 0.17x | 0.02x | 0.15x | 0.00x | -- |
| Operating Cash Flow Growth (YoY) | -- | -- | -293.5% | -- | -- | -- | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
